MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine

Liu Wensheng; Zhang Bo; Hu Qiangsheng; Xu Wenyan; Ji Shunrong; Xu Jin; Ni Quanxing; Yu Xianjun; Xu Xiaowu

doi:10.1186/s12935-019-0948-1

MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine

Cancer Cell Int. 2019 Sep 9:19:232. doi: 10.1186/s12935-019-0948-1. eCollection 2019.

Authors

Liu Wensheng^{1

2

3}, Zhang Bo^{1

2

3}, Hu Qiangsheng^{1

2

3}, Xu Wenyan^{1

2

3}, Ji Shunrong^{1

2

3}, Xu Jin^{1

2

3}, Ni Quanxing^{1

2

3}, Yu Xianjun^{1

2

3}, Xu Xiaowu^{1

2

3}

Affiliations

¹ 1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032 Shanghai, China.
² 2Pancreatic Cancer Institute, Fudan University, 200032 Shanghai, People's Republic of China.
³ 3Shanghai Pancreatic Cancer Institute, 200032 Shanghai, China.

Abstract

Background: Methyl-CpG binding domain protein 1 (MBD1), which couples DNA methylation to transcriptional repression, has been implicated in transcriptional regulation, heterochromatin formation, genomic stability, cell cycle progression and development. It has also been proven that MBD1 is involved in tumor development and progression. However, whether MBD1 is involved in tumorigenesis, especially in gallbladder cancer, is totally unknown.

Methods: Human GBC-SD and SGC996 cells were used to perform experiments. Invasion, wound healing and colony formation assays were performed to evaluate cell viability. A CCK-8 assay was performed to assess gallbladder cancer cell viability after gemcitabine treatment. Western blot analysis was used to evaluate changes in protein expression. Human gallbladder cancer tissues and adjacent nontumor tissues were subjected to immunohistochemical staining to detect protein expression.

Results: We found that MBD1 expression was significantly upregulated in gallbladder cancer tissues compared with that in surrounding normal tissues according to immunohistochemical analysis of 84 surgically resected gallbladder cancer specimens. These data also indicated that higher MBD1 expression was correlated with lymph node metastasis and poor survival in gallbladder cancer patients. Overexpression and deletion in vitro validated MBD1 as a potent oncogene promoting malignant behaviors in gallbladder cancer cells, including invasion, proliferation and migration, as well as epithelial-mesenchymal transition. Studies have demonstrated that epithelial-mesenchymal transition is common in gallbladder cancer, and it is well known that drug resistance and epithelial-mesenchymal transition are very closely correlated. Herein, our data show that targeting MBD1 restored gallbladder cancer cell sensitivity to gemcitabine chemotherapy.

Conclusions: Taken together, the results of our study revealed a novel function of MBD1 in gallbladder cancer tumor development and progression through participation in the gallbladder cancer epithelial-mesenchymal transition program, which is involved in resistance to gemcitabine chemotherapy. Thus, MBD1 may be a potential therapeutic target for gallbladder cancer.

Keywords: Chemotherapeutic resistance; Epithelial–mesenchymal transition; Gallbladder cancer; Malignant behavior; Methyl-CpG binding domain protein 1.